More Cambium Bio Ltd news
Cambium Bio LtdASX: CMB

Progenza patent to grant in Europe

Oct 17, 2018 at 10:32 PM EDT · Issued by Cambium Bio Ltd

Filed with ASX · Oct 17, 2018 at 10:32 PM EDT · 2 pages · English

On 6ix: 6ix.com/news/progenza-patent-to-grant-in-europe

Cambium Bio Ltd on 6ix

Earlier from Cambium Bio

  • Regeneus receives R&D tax incentive refund of $2.4mSep 5, 2018
  • Positive clinical trial results for cancer vaccineJul 30, 2018
  • US Patent Office to allow key patent for ProgenzaJul 9, 2018
  • Update on licensing Progenza in JapanJul 3, 2018
  • European Medicines Agency grants Progenza ATMP statusFeb 13, 2018

Later from Cambium Bio

  • Re-Released - Appendix 4C - QuarterlyOct 23, 2018
  • Chinese patent granted for biomarkers for stem cell therapyDec 2, 2018
  • New CEO Appointed to Accelerate Global GrowthJan 22, 2019
  • Response to ASX Appendix 4C Query LetterFeb 21, 2019
  • Directors Provide $2.5M Loan to Extend Funding RunwayFeb 28, 2019
All Cambium Bio news releases↗

Follow Cambium Bio into a list and get an email when it puts out news.

Follow Cambium Bio
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer